This morning, Compass Pathways shared a highly anticipated topline readout that provides a first look at how patients with treatment-resistant depression (TRD) fared in its second, larger (N=581) Phase 3 study of synthetic psilocybin (COMP360). Notably, the present study (COMP006) administered two doses of either 1 mg, 10 mg, or 25 mg of psilocybin 3 weeks apart, with the readout from this study…
